Current oral treatments for erectile dysfunction

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 11, 2002, Pages 1613-1629

  Kalsi, J S ^a   Cellek, S ^a   Muneer, A ^a   Kell, P D ^a   Ralph, D J ^a   Minhas, S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Erectile dysfunction; Impotence; Oral; Pharmacotherapy

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; APOMORPHINE; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; DOXAZOSIN; GUANYLATE CYCLASE; HALOPERIDOL; METOCLOPRAMIDE; NITRATE; NITRIC OXIDE; PAPAVERINE; PHENTOLAMINE; PHENTOLAMINE MESYLATE; PHOSPHODIESTERASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PLACEBO; PRAZOSIN; PROSTAGLANDIN E1; RHO KINASE; SILDENAFIL; TADALAFIL; TERAZOSIN; TRAZODONE; UNINDEXED DRUG; VARDENAFIL; VASOACTIVE AGENT; VASOACTIVE INTESTINAL POLYPEPTIDE; YOHIMBINE; CELL RECEPTOR; CGMP BINDING, CGMP SPECIFIC 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CGMP-BINDING, CGMP-SPECIFIC 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC GMP PHOSPHODIESTERASE; PROTEIN SERINE THREONINE KINASE; RHO-ASSOCIATED KINASE; SIGNAL PEPTIDE; SOLUBLE GUANYLYL CYCLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; ERECTILE DYSFUNCTION; HEADACHE; HUMAN; HYPOTENSION; MALE; NAUSEA; NONHUMAN; NOSE CONGESTION; PENIS ERECTION; PENIS PROSTHESIS; RAT; REVIEW; SATISFACTION; SEXUAL INTERCOURSE; VACUUM; VASCULAR SURGERY; DRUG ANTAGONISM; IMPOTENCE; INNERVATION; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PENIS;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ADMINISTRATION, ORAL; ADRENERGIC ALPHA-ANTAGONISTS; DOPAMINE AGONISTS; GUANYLATE CYCLASE; HUMANS; IMPOTENCE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PENIS; PHOSPHODIESTERASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 0036850902     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.11.1613     Document Type: Review

References (129)

1. National Institutes of Health. Impotence. NIH Consensus Statement (1992) 10:1-33.
2. AYTAÇ IA, MCKINLAY JB, KRANE RJ: The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. (1999) 84:450-456.
3. FELDMAN HA, GOLDSTEIN I, HATZICHRISTOU DG, KRANE RJ, MCKINLAY JB: Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J. Urol. (1994) 151:54-61.
4. CHUN J, CARSON CC III: Physician-patient dialogue and clinical evaluation of erectile dysfunction. Urol. Clin. North Am. (2001) 28:249-258.
5. CHEW KK, EARLE CM, STUCKEY BG, JAMROZIK K, KEOGH EJ: Erectile dysfunction in general medicine practice: prevalence and clinical correlates. Int. J. Impot. Res. (2000) 12:41-45.
6. National Center for Health Statistics, Centers for Disease Control and Prevention. Life expectancy at birth by race and sex, 1929-1997. Nat. Vital Stat. Rep. (1999) 47(28):32.
7. BRAUN M, WASSMER G, KLOTZ T, REIFENRATH B, MATHERS M, ENGELMANN U: Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey.' Int. J. Impot. Res. (2000) 12:305-311.
8. GIULIANO F, RAMPIN O: Central neural regulation of penile erection. Neurosci. Biobehav. Rev. (2000) 24:517-533.
9. LUITEN PGM, TER HORST GJ, KARST H, STEFFENS AB: The course of paraventricular hypothalamic efferents to autonomic structures in medulla and spinal cord. Brain Res. (1985) 329:374-378.
10. STEERS WD: Neural pathways and central sites involved in penile erection: neuroanatomy and clinical implications. Neurosci. Biobehav. Rev. (2000) 24:507-516.
11. ARGIOLAS A, MELIS MR: Neuromodulation of penile erection: an overview of the role of neurotransmitters and neuropeptides. Prog. Neurobiol. (1995) 47:253-255.
12. BENASSI-BENELLI A, FERRARI F, PELLEGRINI QUARRANTOTTI B: Penile erection induced by apomorphine and N-n-propyl-norapomorphine in rats. Arch. Int. Pharmacodyn. (1979) 242:241-247.
13. ANDERSSON K-E, WAGNER G: Physiology of penile erection. Physiol. Rev. (1995) 75:191-236.
14. SCALETTA LL, HULL EM: Systemic or intracranial apomorphine increases copulation in long-term castrated male rats Pharmacol. Biochem. Behav. (1990) 37:471-475.
15. MELIS MR, STANCAMPIANO R, ARGIOLAS A: Hippocampal oxytocin mediates apomorphine-induced penile erection and yawning. Pharmacol. Biochem. Behav. (1992) 42:61-66.
16. CHUANG AT, STEERS WD: Neurophysiology of penile erection. In Textbook of Erectile Dysfunction. Carson CC, Kirby RS, Goldstein I (Eds). Isis Medical Media, Oxford, UK (1999):59-72.
17. MARSON L AND MCKENNA KE: A role for 5-hydroxytryptamine in descending inhibition of spinal sexual reflexes. Exp. Brain Res. (1992) 88:313-320.
18. FINBERG JP, VARDI Y: Inhibitory effect of 5-hydroxytryptamine on penile erectile function in the rat. Br. J. Pharmacol. (1990)101:698-702.
19. BANCILA M, VERGE D, RAMPIN O et al.: 5-Hydroxytryptamine 2c receptors on spinal neurons controlling penile erection in the rat. Neuroscience (1999)92:1523-1537.
20. HEDLUND P, NY L, ALM P, ANDERSSON KE: Cholinergic nerves in human corpus cavernosum and spongiosum contain nitric oxide synthase and heme oxygenase. J. Urol. (2000) 164:868-875.
21. CELLEK S, MONCADA S: Nitrergic control of peripheral sympathetic responses in the human corpus cavernosum: a comparison with other species. Proc. Natl. Acad. Sci. USA (1997) 94:8226-8231.
22. NITAHARA KS, LUE TF: Microscopic anatomy of the penis. In: Textbook of Erectile Dysfunction. Carson CC, Kirby RS, Goldstein I (Eds). Isis Medical Media, Oxford, UK (1999):31-41.
23. SCHMIDT HH, LOHMAN SM, WALTER U: The nitric oxide and cGMP signal transduction system: Regulation and mechanism of action. Biochem. Biophys. Acta (1993) 1178:153-175.
24. FRANCIS SH, TURKO IV, CORBIN JD: Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol. Biol. (2001) 65:1-52.
25. FRANCIS SH, LINCOLN TM, CORBIN JD: Characterization of a novel cGMP binding protein from rat lung. J. Biol. Chem. (1980) 255:620-626.
26. BALLARD SA, GINGELL CJ, TANG K, TURNER LA, PRICE ME, NAYLOR AM: Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J. Urol. (1998) 159:2164-2171.
27. LINCOLN TM: Cyclic GMP and mechanisms of vasodilatation. Pharmacol. Ther. (1989) 41:479-502.
28. LINCOLN TM, CORNWELL TL: Intracellular cyclic GMP receptor proteins. FASEB J. (1993) 7:328-338.
29. CLAPP LH, GURNEY AM: Modulation of calcium movements by nitroprusside in isolated smooth muscle cells. Plugers Arch. (1991) 418:462-470.
30. ARCHER SL, HUANG JM, HAMPL V, NELSON DP, SHULTZ PJ, WEIR EK: Nitric oxide and cGMP cause vasodilation by activation of a charydotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc. Natl. Acad. Sci. USA (1994) 91:7583-7587.
31. FURUKAWA K, OHSHIMA N, TAWADA INATA Y, SHIGKAWA M: Cyclic GMP stimulates Na+/Ca2+ exchange in vascular smooth muscle cells in primary culture. J. Biol. Chem. (1991) 266:12337-12341.
32. YOSHIDA Y, SUN HT, CAI JQ, IMAI S: Cyclic GMP-dependent protein kinase stimulates the plasma membrane Ca2+ pump ATPase of vascular smooth muscle via phosphorylation of a 240-kDa protein. J. Biol. Chem. (1991) 266:19819-19825.
33. KOMALAVILAS P, LINCOLN TM: Phosphorylation of the inositol 1,4,5-triphosphosphate receptor by cyclic GMP-dependent protein kinase. J. Biol. Chem. (1994) 269:8701-8707.
34. CORNWELL TL, PRYZWANSKY KB, WYATT TA, LINCOLN TM: Regulation of sarcoplasmic reticulum protein dephosphorylation by localised cyclic GMP dependent protein kinase in vascular smooth muscle cells. Mol. Pharmacol. (1991) 40:923-931.
35. SCHLOSSMANN J, AMMENDOLA A, ASHMAN K, ZONG X, HUBER A, NEUBAUER G et al.: Regulation of intracellular calcium by a signalling complex of IRAG, IP3 receptor and cGMP kinase Iβ. Nature (2000) 404(6774):197-201.
36. HIRATA M, KOHSE KP, CHANG CH, IKEBE T, MURAD F: Mechanism of cyclic GMP inhibition of inositol phosphate formation in rat aorta segments and cultured bovine aortic smooth muscle cells. J. Biol. Chem. (1990) 265:1268-1273.
37. OSTERLOH I, EARDLEY I, CARSON C, PADMA-NATHAN H: Sildenafil: a selective phosphodiesterase (PDE) 5 inhibitor in the treatment of erectile dysfunction (ED). In: Textbook of Erectile Dysfunction. Carson CC, Kirby RS, Goldstein I (Eds) Isis Medical Media, Oxford, UK (1999):285-308.
38. BERRIDGE MJ: Inositol trisphosphate and calcium signalling. Nature (1993) 361:315-325.
39. HOLMQUIST F, KIRKEBY HJ, LARSSON B, FORMAN A, ALM P, ANDERSSON KE: Functional effects, binding sites and immunolocalization of endothelin-1 in isolated penile tissues from man and rabbit. J. Pharmacol. Exp. Ther. (1992) 261:795-802.
40. COMITER CV, SULLIVAN MP, YALLA SV, KIFOR I: Effect of angiotensin II on corpus cavernosum smooth muscle in relation to nitric oxide environment: in vitro studies in canines. Int. J. Impot. Res. (1997) 9:135-140.
41. BORNMAN MS, DORMEHL IC, FRANZ RC, DU PLESSIS DJ, JACOBS DJ: Platelets and thromboxane A2 in the pathogenesis of aging penile vascular changes and impotence. Arch. Androl. (1986) 17:233-234.
42. WALLIS RM: The pharmacology of sildenafil, a novel and selective inhibitor of phosphodiesterase (PDE) Type 5. Nippon Yakurigaku Zasshi (1999) 114(Suppl. 1):22P-26P.
43. CHUANG AT, STRAUSS JD, MURPHY RA, STEERS WD: Sildenafil, a Type 5 cGMP phosphodiesterase inhibitor specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro. J. Urol. (1998) 160:257-261.
44. GOLDSTEIN I, LUE TF, PADMANATHAN H, ROSEN RC, STEERS WD, WICKER PA: Oral sildenafil in the treatment of erectile dysfunction: Sildenafil Study Group. N. Engl. J. Med. (1998) 338:1397-1404.
45. PRICE DE, GINGELL JC, GEPI-ATTEE S, WAREHAM K, YATES P, BOOLELL M: Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. Diabet. Med. (1998) 15:821-825.
46. DINSMORE WW, HODGES M, HARGREAVES C, OSTERLOH IH, SMITH MD, ROSEN RC: Sildenafil citrate (Viagra) in erectile dysfunction: near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects. Urol. (1999) 53:800-805.
47. RENDELL MS, RAJFER J, WICKER PA, SMITH MD: Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial: Sildenafil Diabetes Study Group. JAMA (1999) 281:421-426.
48. WEBER DC, BIERI S, KURTZ JM, MIRALBELL R: Prospective pilot study of sildenafil for treatment of postradiotherapy erectile dysfunction in patients with prostate cancer. J. Clin. Oncol. (1999) 17:3444-3449.
49. HULTLING C, GIULIANO F, QUIRK F, PENA B, MISHRA A, SMITH MD: Quality of life in patients with spinal cord injury receiving Viagra (sildenafil citrate) for the treatment of erectile dysfunction. Spinal Cord (2000) 38:363-370.
50. MCMAHON CG, SAMALI R, JOHNSON H: Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction. J. Urol. (2000) 64:1192-1196.
51. HUSSAIN IF, BRADY CM, SWINN MJ, MATHIAS CJ, FOWLER CJ: Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J. Neurol. Neurosurg. Psychiatry (2001) 71:371-374.
52. OLSSON AM, PERSSON CA: Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with cardiovascular disease. Int. J. Clin. Pract. (2001) 55:171-176.
53. WAGNER G, MONTORSI F, AUERBACH S, COLLINS M: Sildenafil citrate (VIAGRA) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis. J. Gerontol. A. Biol. Sci. Med. Sci. (2001) 56:M113-M119.
54. LEWIS R, BENNETT CJ, BORKON WD et al.: Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the Erectile Dysfunction Inventory of Treatment Satisfaction Questionnaire. Urol. (2001) 57:960-965.
55. MEULEMAN E, CUZIN B, OPSOMER RJ et al.: A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction. BJU Int. (2001) 87:75-81.
56. BLANDER DS, SANCHEZ-ORTIZ RF, WEIN AJ, BRODERICK GA: Efficacy of sildenafil in erectile dysfunction after radical prostatectomy. Int. J. Impot. Res. (2000) 12:165-168.
57. HATZICHRISTOU DG: Sildenafil citrate: lessons learned from 3 years of clinical experience. Int. J. Impot. Res. (2002) 14(Suppl. 1):S43-S52.
58. MUNEER A, KALSI J, KELL P, MINHAS S: Aetiological factors associated with failure of treatment with sildenafil and outcome. Int. J. Impot. Res. (2002) 14(Suppl. 3):S53.
59. CELLEK S, RODRIGO JA, LOBOS E, FERNANDEZ P, SERRANO J, MONCADA S: Selective nitrergic neurodegeneration in diabetes mellitus, a nitric oxide-dependent phenomenon. Br. J. Pharmacol. (1999) 128:1804-1812.
60. SHABSIGH R, PADMA-NATHAN H, GITTLEMAN M, MCMURRAY J, KAUFMAN J, GOLDSTEIN I: Intracavernosal alprostadil alfadex (EDEX/VIRIDAL) is effective and safe in patients with erectile dysfunction after fading sildenafil (Viagra). Urol. (2000) 55:477-480.
61. GUTIERREZ P, HERNANDEZ P, JIMENEZ A, MAS M: Combining programmed intracavernous PGE1 injections and sildenafil on demand to salvage sildenafil nonresponders. Int. J. Impot. Res. (2002) 14(Suppl. 3):S37.
62. DMITRIEV DG, GAMIDOV SI, OVCHINNIKOV RI, MAZO EB, TIRSI KA: Advantages of combining of sildenafil and alprostadil taken by nonrespondents to monotherapy of erectile dysfunction. Int. J. Impot. Res. (2002) 14(Suppl. 3):S86.
63. LIM PH, LI MK, NG FC et al.: Clinical efficacy and safety of sildenafil citrate (Viagra) in a multi-racial population in Singapore: A retrospective study of 1520 patients. Int. J. Urol. (2002) 9:308-315.
64. FAGELMAN E, FAGELMAN A, SHABSIGH R: Efficacy, safety, and use of sildenafil in urologic practice. Urol. (2001) 57:1141-1144.
65. GABRIELI CB, REGINE F, VINGOLO EM, RISPOLI E, FABBRI A, ISIDORI A: Subjective visual halos after sildenafil (Viagra) administration: Electroretinographic evaluation. Ophthalmol. (2001) 108:877-881.
66. WEBB DJ, MUIRHEAD GJ, WULFF M, SUTTON JA, LEVI R, DINSMORE WW: Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J. Am. Coll. Cardiol. (2000) 36:25-31.
67. JACKSON G, KELTAI M, GILLIES H, CZORNIAK M, KEATING Z: Viagra is well tolerated by subjects with stable angina and erectile dysfunction during incremental treadmill exercise. Eur. Urol. Suppl. (2002) 1:596P.
68. LIM PH, MOORTHY P, BENTON KG: The clinical safety of viagra. Ann. NY Acad. Sci. (2002) 962:378-388.
69. ANGULO J, GADAU M, FERNANADEZ A, GABANCHO S, CUEVAS P, MARTINS T: Tadalafil enhances nitricoxide mediated relaxation of human arterial and trabecular penile smooth muscle. The European Association for the Study of Diabetes (EASD), Glasgow Scotland 2001.
70. PATTERSON B, BEDDING A, JEWELL H, PAYNE C, MITCHELL M: Dose-normalised pharmacokinetics of Tadalafil administered as a single dose to healthy volunteers. Eur. Urol. Suppl. (2002) 1:600P.
71. BROCK GB, MCMAHON CG, CHEN KK et al.: Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J. Urol (2002) 168:1332-1336.
72. SAENZ DE TEJADA I, EMMICK J, ANGLIN G, FREDLUND P, PULLMAN W: The effect of as needed Tadalafil (IC351) on erectile dysfunction in men with diabetes. Int. J. Impot. Res. (2001) 13(Suppl. 4):S46.
73. KLONER R: Cardiovascular profile of tadalafil, a new PDE5 inhibitor. J. Urol. (2002) 167(Suppl. 4):P707.
74. KIM NN, HUANG YH, GOLDSTEIN I, BISCHOFF E, TRAIS AM: Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel selective phosphodiesterase Type 5 inhibitor. Life Sci. (2001) 69:2249-2256.
75. CHOI S, O'CONNELL L, MIN K, MUNARRIZ R, GOLDSTEIN I, BISCHOFF E et al.: Comparison between vardenafil and sildenafil in facilitating pelvic nerve-mediated penile erection in a rabbit model. Int. J. Impot. Res. (2001) 13(Suppl. 4):S16.
76. SAENZ DE TEJADA I, ANGULO J, CUEVAS P et al.: The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int. J. Impot. Res. (2000)13:282-290.
77. STARK S, SACHSE R, LIEDL T, HENSEN J, ROHDE G, WENSING G: Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur. Urol. (2001) 40:181-190.
78. KLOTZ T, SACHSE R, HEIDRIH A, JOCKENHOVEL F, ROHDE G, WENSING G et al.: Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J. Urol. (2001) 19:32-39.
79. PORST H, ROSEN R, PADMANATHAN H et al.: The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase Type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int. J. Impot. Res. (2001) 13:192-199.
80. PORST H, PADMA-NATHAN H, THIBONNIER M, EARDLEY I: Efficacy and safety of vardenafil, a selective Phosphodiesterase 5 inhibitor, in men with erectile dysfunction on antihypertensive therapy Eur. Urol. Suppl. (2002) 1:599P.
81. BROCK G, TAYLOR T, SEGER M: Efficacy and tolerability of vardenafil in males with erectile dysfunction following radical prostatectomy. Eur. Urol. Suppl. (2002) 1:598P.
82. PRYOR J: Vardenafil: update on clinical experience. Int. J. Impot. Res. (2002) 14(Suppl. 1):S65-S69.
83. THADANI U, MAZZU A: Exercise-induced ischaemia was not adversely affected by vardenafil during an exercise stress test in men with coronary artery disease. Eur. Urol. Suppl. (2002) 1:595P.
84. CORBIN JD, FRANCIS SH: Pharmacology of phosphodiesterase-5 inhibitors. Int. J. Clin. Pract. (2002) 56:453-459.
85. BECKER AJ, STIEF CG, MACHTENS S, SCHULTHEISS D, HARTMANN U, TRUSS MC et al.: Oral phentolamine as treatment for erectile dysfunction. J. Urol. (1998) 159:1214-1216.
86. GOLDSTEIN I: Oral phentolamine: an α-1, α-2 adrenergic antagonist for the treatment of erectile dysfunction. Int. J. Impot. Res. (2000) 12(Suppl. 1):S75-S80.
87. GOLDSTEIN I, CARSON C, ROSEN R, ISLAM A: Vasomax for the treatment of male erectile dysfunction. World J. Urol. (2001) 19:51-56.
88. HOFFMAN BB, LEFKOWITZ RJ: α-adrenergic receptor subtypes. N. Engl. J. Med. (1980) 302:1390-1396.
89. 2-adrenoreceptor. Pharmacol. Rev. (1983) 35:143-180.
90. MORALES A: Yohimbine in erectile dysfunction: the facts. Int. J. Impot. Res. (2000) 12(Suppl. 1):S70-S74.
91. RILEY AJ, GOODMAN RE, KELLETT JM, ORR R: Double blind trial of yohimbine hydrochloride in the treatment of erection inadequacy. Sexual and Marital Therapy (1989) 4:17-26.
92. ERNST E, PITTLER MH: Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J. Urol. (1998) 159:433-436.
93. O'BRIEN AAJ, BULPITT CJ: Hypertensive disease. In: Avery's Drug Treatment (4th edn). Speight TM, Holford HG (Eds), Blackwell Science, Auckland, New Zealand (1997):906.
94. PETERSON CA, BENNETT AH, HELLSTROM WJ et al.: Erectile response to transurethral alprostadil, prazosin and alprostadil-prazosin combinations. J. Urol. (1998)159:1523-1528.
95. DE ROSE AF, CARMIGNANI G, CORBU C, GIGLIO M, TRAVERSO P, NASELLI A et al.: Observational multicentric trial performed with doxazosin: evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia. Urol. Int. (2002) 68:95-98.
96. DE ROSE AF, GIGLIO M, TRAVERSO P, LANTIERI P, CARMIGNANI G: Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy. Int. J. Impot. Res. (2002) 14:50-53.
97. VAIDYANATHAN S, SONI BM, SINGH G, SETT P, KRISHNAN KR: Prolonged penile erection association with terazosin in a cervical spinal cord injury patient. Spinal Cord (1998) 36:805.
98. TRAISH A, KIM NN, MORELAND RB, GOLDSTEIN I: Role of α adrenergic receptors in erectile function. Int. J. Impot. Res. (2000) 12(Suppl. 1):S48-S63.
99. MEINHARDT W, SCHMITZ PI, KROPMAN RF et al.: Trazodone, a double blind trial for treatment of erectile dysfunction. Int. J. Impot. Res. (1997) 9:163-165.
100. ENZLIN P, VANDERSCHUEREN D, BONTE L, VANDERBORGHT W, DECLERCQ G, DEMYTTENAERE K: Trazodone: a double-blind, placebo-controlled, randomized study of its effects in patients with erectile dysfunction without major organic findings. Int. J. Impot. Res. (2000) 12:223-228.
101. LAL S: Apomorphine in the evaluation of dopaminergic function in man. Prog. Neuropsychopharmacol. Biol. Psychiatry (1988) 12:117-164.
102. CHEN KK, CHAN SH, CHANG LS: Dopaminergic neurotransmission at the paraventricular nucleus of hypothalamus in central regulation of penile erection in the rat. J. Urol. (1999) 162:237-242.
103. BENASSI-BENELLI A, FERARI F, PELLEGRINI QUARRANTOTTI B: Penile erection induced by apomorphine and N-n-propyl-norapomorphine in rats. Arch. Int. Pharmacodyn. (1979) 242:241-247.
104. HEATON JP, VARRIN S: Metoclopramide decreases apomorphine-induced yawning and penile erection. Pharmacol. Biochem. Behav. (1991) 38:917-920.
105. VALLONE D, PICETTI R, BORRELLI E: Structure and function of dopamine receptors. Neurosci. Bibehav. Rev. (2000) 24:125-132.
106. GIULIANO FA, ALLARD J, RAMPIN O, DROUPY S, ALEXANDRE L, BERNABE, J: Spinal proerectile effect of apomorphine in the anesthetized rat. Int. J. Impot. Res. (2001) 13:110-115.
107. SEAGRAVES RT, BARI M, SEAGRAVES K, SPIRNA P: Effect of apomorphine on penile tumescence in men with psychogenic impotence. J. Urol. (1991) 145:1174-1175.
108. DULA E, BUKOFZER S, PERDOK R, GEORGE M: Double-blind, cross-over comparison of 3 mg apomorphine SL with placebo and 4 mg apomorphine SL in male erectile dysfunction. Eur. Urol. (2001) 39:558-564.
109. HEATON JP: Characterizing the benefit of apomorphine SL (Uprima) as an optimized treatment for representative populations with erectile dysfunction. Int. J. Impot. Res. (2001) 13(Suppl. 3):S35-S39.
110. MIRONE VG, STIEF CG: Efficacy of apomorphine SL in erectile dysfunction. BJU Int (2001) 889(Suppl. 30):25-29.
111. HEATON JPW, SLEEP, DJ, PERDOK RJ, PADLEY RJ: Uprima success increased with consecutive administrations. Int. J. Impot. Res. (2002) 14(Suppl.3):S21.
112. MONTEJO AL, LLORCA G, IZQUIERDO JA, RICO-VILLADEMOROS F: Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J. Clin. Psychiatry (2001) 62(Suppl. 3):10-21.
113. KEENE LC, DAVIES PH: Drug-related erectile dysfunction. Adverse Drug React. Toxicol. Rev. (1999)18:5-24.
114. HEATON JPW, SLEEP DJ, PERDOK R, RESCEK ME: Apomorphine SL 2mg and 3mg is well tolerated and effective in men with ED concurrently taking antidepressant medication. Eur. Urol. Suppl. (2002) 1:602P.
115. SOMLYO AP, SOMLYO AV: Signal transduction by G-proteins, Rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J. Physiol. (2000) 522:177-185.
116. REES RW, RALPH DJ, ROYLE M, MONCADA S, CELLEK S: Y-27632, an inhibitor of Rho-kinase, antagonizes noradrenergic contractions in the rabbit and human penile corpus cavernosum. Br. J. Pharmacol. (2001) 133:455-458.
117. CHITALEY K, WINGARD CJ, WEBB RC et al.: Antagonism of rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat. Med. (2001) 7:119-122
118. CELLEK S, MONCADA S: Nitrergic neurotransmission in the physiology of penile erection and pathophysiology of erectile dysfunction. In: Nitric Oxide and the Peripheral Nervous System. Toda N, Moncada S, Furchgott R, Higgs EA. Portland Press, London, UK (2000):61.
119. FRIEBE A, KOESLING D: Mechanism of YC-1 induced activation of soluble guanylyl cyclase. Mol. Pharmacol. (1998) 53:123-127.
120. WEGENER JW, GATH I, FORSTERMANN U, NAWRATH H: Activation of soluble guanylyl cyclase by YC-1 in aortic smooth muscle but not in ventricular myocardium from rat. Br. J. Pharmacol. (1997) 122:1523-1529.
121. LIU SP, GUH JH, TENG CM, LAI MK, HSIEH JT: YC-1, a NO-independent guanylate cyclase stimulator, relaxes rabbit cavernous smooth muscle via increasing intracellular cyclic GMP. Int. J. Impot. Res. (2000) 12(Suppl. 2):S18.
122. MIZUSAWA H, HEDLUND P, BRIONI JD, SULLIVAN JP, ANDERSSON KE: Nitric oxide independent activation of guanylate cyclase by YC-1 causes erectile responses in the rat. J. Urol. (2002) 167:2276-2281.
123. NAKANE M, HSIEH G, MILLER LN et al.: Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1. Int. J. Impot. Res. (2002) 14:121-127.
124. HSEIH GC, O'NEILL AB, NAKONE M, MORELAND RS, BRIONI JD: YC-1, a soluble guanylate cyclase activator potentiates the NO/cGMP pathway and facilitates penile erection in rats. J. Urol. (2002) 167(Suppl. 4):939.
125. GALLE J, ZABEL U, HUBNER U, HATZELMANN A, WAGNER B, WANNER C et al.: Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br. J. Pharmacol. (1999) 127:195-203.
126. WOHLFART P, MALINSKI T, RUETTEN H et al.: Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase. Br. J. Pharmacol. (1999) 128:1316-1322.
127. MORELAND RB, HSEIH GC, NAKONE M et al.: Novel soluble guanylate cyclase activators A-344905 and A-350619 activate sGC in vitro and facilitate erection in rats. J. Urol. (2002) 167(Suppl. 4):938.
128. BISCHOFF E, SCHRAMM M, STRAUB A, FEURER A, STASCH JP: BAY41-2272 a stimulator of soluble guanylyl cyclase induces NO-dependent penile erection in vivo. (2002) Int. J. Impot. Res. 14(Suppl. 3):S43.
129. KALSI JS, REES RW, HOBBS AJ, et al.: BAY41-2272 a novel NO-independent soluble guanylate cyclase inhibitor relaxes human and rabbit corpus cavernosum. Int. J. Impot. Res. 14(Suppl. 3):S2.